Evidence conflicts over efficacy of monoclonal antibodies in severe COVID

Must Read
Feb 26, 2021

“We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances.”

Mary Van Beusekom | News Writer | CIDRAP News

Feb 26, 2021
“We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances.”Read More

- Advertisement -spot_img

Leave a reply

Please enter your comment!
Please enter your name here

- Advertisement -spot_img
Latest News
- Advertisement -spot_img

More Articles Like This

- Advertisement -spot_img